--- a
+++ b/clusters/9knumclustersv2/clust_1240.txt
@@ -0,0 +1,33 @@
+The subject has received another investigational agent within  days of the first dose of study drug
+The subject has received any other type of investigational agent within  days before the first dose of study treatment
+The participant has received any other type of investigational agent within  days before the first dose of study treatment
+The subject has received any other type of investigational agent within  days before the first dose of study treatment
+The participant has received another investigational agent within  days of the first dose of study drug
+Received any investigational agent within the  days before the start of study treatment (st dose of fludarabine)
+The subject has received any other type of investigational agent within  days before the first dose of study treatment
+Received another investigational agent (defined as any agent/device that has not received regulatory approval for any indication) within  days of the first dose of study drug for a nonmyelosuppressive agent, or  days of the first dose of study drug for a myelosuppressive agent
+Received any investigational agent within the  days before the start of study treatment (st dose of fludarabine phosphate [fludarabine])
+Received any investigational agent within the  days before the start of study treatment (st dose of fludarabine)
+mCRPC EXPANSION COHORT: The patient has received any other type of investigational agent within  days before the first dose of study treatment
+The subject has received any other type of investigational agent within  days before the first dose of study treatment
+At least  days after the last dose of a biologic agent.
+Receipt of any other type of investigational agent within  days before the first dose of study treatment
+The subject has received any other type of investigational agent within  days before the first dose of study treatment
+Any other type of investigational agent within  weeks before the first dose of study treatment
+RENAL COHORT: The subject has received any other type of investigational agent within  days before the first dose of study treatment
+The subject has received any other type of investigational agent within  days before the first dose of study treatment
+Any other type of investigational agent within  days before the first dose of study treatment
+Any anti-cancer treatment within  days or any investigational agent within  days before the first dose of study drug.
+Investigational agent received within  days prior to the first dose of study drug
+The subject has received any other type of investigational agent within  days before the first dose of study treatment
+The subject has received any other type of investigational agent within  days before the first dose of study treatment
+Having received an investigational agent within  days prior to the first dose of study treatment
+The subject has received any other type of investigational agent within  days before the first dose of study treatment
+The participant has received any other type of investigational agent within  days before the first dose of study treatment
+Treatment with any investigational agent within  days before the first dose of study treatment
+Having received an investigational agent with  days of receiving the first dose of study drug on this trial
+Use of any other type of investigational agent or treatment concurrently or within  days before the first dose of study treatment
+The subject has received any other type of investigational agent within  days before the first dose of study treatment
+The subject has received any other type of investigational agent within  days before the first dose of study treatment
+The subject has received any investigational agent within  days before the first dose of study treatment
+Received any investigational agent within the  days before the start of study treatment (st dose of ALT-)